Related Experiment Videos
Dose linearity of clonidine after transdermal application
1Department of Research and Development, Boehringer Ingelheim KG, Ingelheim, Germany.
Summary
Individualized dosing of clonidine transdermal systems (TTS) is crucial for effective hypertension treatment. This study confirms that increasing clonidine dosage in TTS leads to a linear increase in released drug and bioavailability.
Area of Science:
- Pharmacokinetics and Drug Delivery
- Cardiovascular Pharmacology
Background:
- Optimal antihypertensive treatment requires individualized dosing.
- Clonidine transdermal systems (TTS) offer potential for dose titration.
Purpose of the Study:
- To determine if increasing clonidine TTS size linearly increases bioavailable drug.
- To validate dose-release linearity in clonidine TTS.
Main Methods:
- Healthy volunteers applied three different clonidine TTS dosages for 7 days.
- Residual clonidine in patches and plasma clonidine levels were measured.
- Area Under the Plasma Concentration-Time Curve (AUC) was calculated using the trapezoidal rule.
Main Results:
- Released drug amounts and AUC increased linearly with clonidine dose (2.5-7.5 mg).
- Regression analysis confirmed a linear relationship between released drug and AUC.
- Demonstrated predictable drug release and bioavailability with increasing TTS dosage.
Conclusions:
- Clonidine TTS allow for linear dose adjustments, supporting individualized antihypertensive therapy.
- The findings validate the predictable pharmacokinetic profile of clonidine TTS across tested doses.
- This supports the use of clonidine TTS for tailored blood pressure management.